Oncolytic viruses are one of the most promising novel therapeutics for malignant cancers.
They selectively infect and kill cancer cells while sparing the normal counterparts, expose …

The specificity of a given virus for a cell type, tissue or species—collectively known as viral
tropism—is an important factor in determining the outcome of viral infection in any particular …

Chikungunya virus (CHIKV) is an arthritogenic mosquito-transmitted alphavirus that is
undergoing reemergence in areas around the Indian Ocean. Despite the current and …

Current standard treatments of cancer can prolong survival of many cancer patients but
usually do not effectively cure the disease. Oncolytic virotherapy is an emerging therapeutic …

Human disease caused by highly pathogenic avian influenza (HPAI) H5N1 can lead to a
rapidly progressive viral pneumonia leading to acute respiratory distress syndrome. There is …

Many common neoplasms are still noncurative with current standards of cancer therapy.
More therapeutic modalities need to be developed to significantly prolong the lives of …

Inflammatory cytokines, such as tumor necrosis factor and the members of the interferon
family, are potent mediators of the innate anti-viral immune response. The intracellular anti …

Myxoma virus (MYXV), a Leporipoxvirus, is being developed as an oncolytic virotherapeutic
for the treatment of a variety of human cancers. MYXV tropism for human cancer cells is …

Oncolytic virotherapy has been proposed as an ablative and immunostimulatory treatment
strategy for solid tumors that are resistant to immunotherapy alone; however, there is a need …

Myxoma virus (MYXV) gained importance throughout the twentieth century because of the
use of the highly virulent Standard Laboratory Strain (SLS) by the Australian government in …